Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Vera Therapeutics, Inc. (NASDAQ:VERA) today announced data from the ORIGIN Phase 3 trial of atacicept in IgA nephropathy (IgAN)...
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $...
Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing tr...
Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.
B of A Securities analyst Dina Ramadane initiates coverage on Vera Therapeutics (NASDAQ:VERA) with a Buy rating and announce...
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and lowers the price target from $...
- SEC Filing
